Home / Business and Economy / Biotech Investment Fuels Asian Rare Disease Access
Biotech Investment Fuels Asian Rare Disease Access
27 Oct
Summary
- Kos Biotechnology Partners made a strategic investment in Golden Age Health.
- The funding will expand Golden Age Health's presence in Greater China and Asia-Pacific.
- The partnership aims to accelerate cross-border biotech innovation into Asia.
Kos Biotechnology Partners, a global life sciences investment firm, has made a strategic investment in Golden Age Health (GAH) via its Kos BioVentures fund. This collaboration is set to enhance GAH's commercial reach across Greater China and the Asia-Pacific region.
The investment will drive the expansion of GAH's portfolio and commercial infrastructure. Golden Age Health specializes in delivering approved rare and specialty disease medicines to underserved patient populations in Greater China, Southeast Asia, and the Gulf regions. This partnership seeks to expedite the cross-border transfer of biotech innovation between Western and Asian markets.
Alex Tzoukas of Kos Biotechnology Partners highlighted Golden Age Health's capability in navigating complex regulatory and commercial landscapes. He expressed enthusiasm for scaling GAH's operations and creating a reciprocal pathway for Asian biotech innovation into Western pipelines.
Michel Vounatsos, Co-Founder and Executive Chairman of Golden Age Health, welcomed Kos Biotechnology Partners as a strategic investor. He emphasized their shared vision of patient access and the value of Kos's expertise in scaling their rare disease medicine portfolio in Asia.
